Cerevel Therapeutics Holdings Inc
(FRA:673)
€
23.6
0 (0%)
Market Cap: 7.57 Bil
Enterprise Value: 7.13 Bil
PE Ratio: 0
PB Ratio: 14.49
GF Score: 20/100 Cerevel Therapeutics Holdings Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 13, 2021 / 02:15PM GMT
Matthew Harrison
Morgan Stanley - Analyst
Great. Good morning, everybody, and thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Very pleased to have Cerevel with us for the next session. Before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures.
And with that, I'm going to turn it over to Tony Coles, the CEO at Cerevel, to make some opening comments and get us started. Tony, I think you're on mute.
Tony Coles
Cerevel Therapeutics - CEO & Chairperson of the Board of Directors
Thank you.
Matthew Harrison
Morgan Stanley - Analyst
There you go.
Tony Coles
Cerevel Therapeutics - CEO & Chairperson of the Board of Directors
I think that happens automatically with the switchover. Good
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot